Qrativ
Qrativ uses AI to find new therapeutic uses for existing molecules, accelerating treatments for diseases with unmet medical needs. Its Darwin.ai platform applies machine learning and artificial intelligence to analyze biological, chemical, and clinical data and generate drug‑repurposing hypotheses. The company operates as a B2B computational drug‑repurposing and discovery platform serving pharmaceutical, biotechnology, and research organizations. Key technologies include AI/ML‑driven modeling and computational analytics for molecular and clinical data. Qrativ’s offering targets unmet therapeutic areas to shorten research timelines and expand treatment options.
Qrativ
Qrativ uses AI to find new therapeutic uses for existing molecules, accelerating treatments for diseases with unmet medical needs. Its Darwin.ai platform applies machine learning and artificial intelligence to analyze biological, chemical, and clinical data and generate drug‑repurposing hypotheses. The company operates as a B2B computational drug‑repurposing and discovery platform serving pharmaceutical, biotechnology, and research organizations. Key technologies include AI/ML‑driven modeling and computational analytics for molecular and clinical data. Qrativ’s offering targets unmet therapeutic areas to shorten research timelines and expand treatment options.
TL;DR
Focus: AI-driven drug repurposing platform
Key partner: Mayo Clinic
Founded: 2017
Industry: Biotechnology
Status (per profiles): Listed as closed in 2022 in some profiles
Company Overview
Problem Domain
Drug repurposing / systematic identification of new therapeutic applications for existing molecules.
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
Investors reported to include Matrix and Mayo Clinic; total funding amount reported as 8,300,000 USD in company snapshot.
Investor Signal
“Mayo Clinic strategic involvement as partner and investor”